Vanguard Capital Management
NVCR icon

Vanguard Capital Management’s NovoCure NVCR Stock Holding History

Vanguard Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.3M Buy
4,903,633
+221,569
+5% +$3.35M ﹤0.01% 1717
2026
Q1 		$51M Buy
+4,682,064
New +$58.5M ﹤0.01% 1837

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management's NVCR Position: Q2 2026 in Review

Vanguard Capital Management increased its NovoCure (NVCR) stake by 4.7% in Q2 2026, buying an estimated $3.35M and bringing the position to 4,903,633 shares worth $74.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Vanguard Capital Management first reported a position in NVCR in Q1 2026 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Vanguard Capital Management held 4,903,633 shares of NovoCure worth $74.3M as of Q2 2026.
  • Vanguard Capital Management bought 221,569 NovoCure shares in Q2 2026, an estimated $3.35M.
  • NovoCure made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1717 holding.
  • Vanguard Capital Management first reported a position in NovoCure in Q1 2026 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.